Here are the first 10 Medicare drugs the government will negotiate lower prices for
Here are the first 10 Medicare drugs the government will negotiate lower prices for
Here are the first 10 Medicare drugs the government will negotiate lower prices for
The Centers for Medicare and Medicaid Services (CMS) early Tuesday announced the first 10 drugs chosen for Medicare price negotiation under the Inflation Reduction Act (IRA).
These single-source drugs were chosen based on their eligibility under the IRA and are the “highest total Part D gross covered prescription drug costs” under Medicare Part D, according to the CMS. In total, these medications account for $50.5 billion in total gross Part D costs.
Negotiations over these drugs, if manufacturers agree to the process, will take place over 2023 and 2024. Drugmakers have until Oct. 1 to sign agreements.